study_title: Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape

study_first_author: Starr

study_year: 2021

study_journal: bioRxiv

study_url: https://www.biorxiv.org/content/10.1101/2021.04.06.438709v1

spike: Wuhan-Hu-1

notes: "The data are from here, with S2X259 removed (separate paper): https://github.com/jbloomlab/SARS-CoV-2-RBD_MAP_Vir_mAbs/blob/main/results/supp_data/vir_antibodies_raw_data.csv"

conditions:
  S309:
    type: antibody
    subtype: class 3
    year: 2021
    alias: VIR-7831
  S2H97:
    type: antibody
    subtype: class 4
    year: 2021
  S304:
    type: antibody
    subtype: class 4
    year: 2021
  S2X35:
    type: antibody
    subtype: class 4
    year: 2021
  S2E12:
    type: antibody
    subtype: class 1
    year: 2021
  S2X16:
    type: antibody
    subtype: class 2
    year: 2021
  S2H58:
    type: antibody
    subtype: class 2
    year: 2021
  S2H13:
    type: antibody
    subtype: class 2
    year: 2021
  S2D106:
    type: antibody
    subtype: class 2
    year: 2021
  S2X58:
    type: antibody
    subtype: class 2
    year: 2021
  S2H14:
    type: antibody
    subtype: class 1
    year: 2021
  S2X227:
    type: antibody
    subtype: class 3
    year: 2021

